Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
株式のランク #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
株価
$0.00244926
時価総額
$51.67K
変化(1日)
5.88%
変化(1年)
110.15%
GB
取引 Nuformix plc (NFX)

カテゴリー

Nuformix plc(NFX)のEPS
September 2025 時点のEPS TTM: $0.00
Nuformix plcの最新の財務報告と株価によると、同社の現在のEPS(TTM)は$0.00です。2024年末には、EPSは$-0.01で、2023年のEPS$0.00と減少でした。
Nuformix plcのEPS履歴(2014から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) 0.00 -100.00%
2025 0.00 -100.00%
2024 $-0.01 520.00%
2023 0.00 -60.00%
2022 0.00 -16.67%
2021 0.00 50.00%
2020 0.00 -57.45%
2019 0.00 -31.88%
2018 $-0.01 -23.33%
2017 $-0.01 8.43%
2016 $-0.01 0.00%
2014 0.00 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$3.62 -402,577.78%
DK
$15.47 -1,718,988.89%
US
$43.12 -4,791,211.11%
US
$9.62 -1,069,077.78%
BE
$2.98 -331,211.11%
AU